Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Visual perception in deep neural networks (DEEPCEPTION)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Global Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Belgium,United States
Call: Marie Skłodowska-Curie Individual Fellowships (IF-GF) (H2020-MSCA-IF-2015, 2015)
Start date: 2016-10-01
End date: 2019-09-30
Duration (months): 36.0
Total project cost (EUR): 258530.4
EU funding (EUR): 258530.4
Participants: 2
Project status: CLOSED

How do we recognize what we see? Despite the deceptive ease of perceiving things, explaining how we see turns out to be a supremely difficult task. Only recently advances in computer vision finally brought a class of models, known as deep neural nets, that are capable of matching human performance in several visual perception tasks. In this project, we aim to employ the knowledge how human visual system processes visual information in order to critically evaluate and improve the existing models of vision. Our aim is twofold. On the one hand, little is known yet how well deep nets can account for a huge variety of tasks that human visual system faces daily. We will perform a broad battery of tests in order to shed light on the power of deep nets and to spot potential limitations. Capitalizing on these shortcomings, in the second part of this project we aim to improve the existing technology by introducing novel algorithms based on behavioral and neural data of humans. Taken together, this project will lay a solid foundation for the psychologically- and biologically-based development of the next generation of deep nets.

Keywords: deep learning,neural networks,rapid visual perception,image segmentation
Characterization and Modelling of dislocation-INterface Interactions in MetAllic Laminates at multiple scales (MINIMAL)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Information Science and Engineering
Countries involved: Spain
Call: Individual Fellowships (H2020-MSCA-IF-2016, 2016)
Start date: 2018-05-01
End date: 2019-04-30
Duration (months): 12.0
Total project cost (EUR): 85060.8
EU funding (EUR): 85060.8
Participants: 1
Project status: CLOSED

The global market will increase from $11 billion in 2012 to $22.5 billion in 2018 for micro electro mechanical systems (MEMS), and from $1.9 billion in 2012 to $6.6 billion in 2018 for BioMEMS. Recently, metallic nanolaminates have attracted application as mechanical parts in MEMS and BioMEMS manufacturing. This is due to their superior properties, i.e. large flow strength, high indentation hardness, excellent ductility, good radiation damage resistance, qualified electrical/magnetic response, and promising fatigue/failure resistance. In order to address the performance of metallic nanolaminates and to reduce materials’ failure and cost under different service conditions, better analysis/predictive tools are required for dislocation-interface interactions. The improved analysis/predictive tools will allow designing more advanced nanolaminate materials. However, to develop such analysis/predictive tools, it entails (a) in-depth understanding of the physical mechanisms behind dislocation-interface interactions, (b) accurate in-situ mechanical testing data at different length scales from micro- to nanometers, and (c) efficient numerical modelling to predict dislocation-interface interactions. Through this Marie Skłodowska-Curie action, we will contribute significantly towards improving these analysis/predictive tools from two aspects, including (i) providing the scientific knowledge behind dislocation-interface interactions, and (ii) establishing improved numerical models to predict dislocation-interface failure during service. Meanwhile, the new advanced nanolaminate materials with enhanced properties will also be proposed based on the generated knowledge. In addition, the researcher and the host organization will benefit from the two-way transfer of knowledge between them.

Keywords: characterization,modelling,dislocation interface,nanolaminates,in situ mechanical testing
MOTORCYCLE ALL-IN-ONE SMART TOUR INTEGRATED ROAD SECURITY SYSTEM (STS)

Framework: Horizon 2020 — Societal Challenges
Programme: Smart, green and integrated transport
Action type: SME instrument
Countries involved: Slovenia
Call: Small business innovation research for Transport and Smart Cities Mobility (H2020-SMEINST-1-2016-2017, 2017)
Start date: 2017-08-01
End date: 2018-01-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Motorcyclists are, together with cyclists and pedestrians, the most vulnerable participants in road traffic. In 2016, there were more than 4300 fatalities among motorcyclists in the EU. The STS is an Advanced Driver Assistance System (ADAS) representing an INNOVATIVE INTEGRATED MOTORCYCLE ROAD TRAFFIC SECURITY SOLUTION, providing: most reliable and accurate self-cancelling turn signals, deceleration warning, driving data export and specific computer algorithm enabling processing and evaluation of more than 20 parameters and 300 data elements per second supporting the STS functional security features. It can be integrated on all types of motorcycles. An additional advantage of the STS is also the un-invasive installation. Motorcyclists are involved in numerous high-risk situations due to the lack of motorcycle-integrated security enhancing solutions that are taken for granted in cars (e.g. self-cancelling turn signals, deceleration warning etc.). The currently available alternative solutions either address only one security-related issue at a time, are not accurate enough, or are invasive installation-wise and interfere with the driving experience. For the future, our solution has the potential to become the functional security system for motorcyclists, integrating also functions like e-Call, geo location, kill-switch, connectivity with the helmet, audio warnings, to list a few. On the global level the STS is the only solution enabling the export, evaluation and analysis of big data in a mobile app. The STS is addressing two markets: motorbike (elements) manufacturers and motorbike owners. Extensive research has shown that there are clearly articulated needs for a reliable, accurate and integrated security-enhancing solution in both segments. In Phase 1 we are going to assess the technical characteristics of the solution and the potentials for its commercialisation. Further development of the solution, to move forward to TRL 9, is planned for Phase 2.

Keywords: motorcycle,safety,smart system,self cancelling turn signals,backlight warning,data export,data,evaluation,advanced driver asistance system,functional security
Bioinformatics for spatial metabolomics (METASPACE)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Health care provision and integrated care
Action type: Research and Innovation actions
Countries involved: Germany,Germany,Germany,Belgium,France,United States,United Kingdom
Call: Advancing bioinformatics to meet biomedical and clinical needs (H2020-PHC-2014-two-stage, 2014)
Start date: 2015-07-01
End date: 2018-06-30
Duration (months): 36.0
Total project cost (EUR): 2998944.0
EU funding (EUR): 2998944.0
Participants: 8
Project status: CLOSED

Metabolomics is recognized as a crucial scientific domain, promising to advance our understanding of biology, physiology, and medicine. The emergence of high-resolution imaging mass spectrometry (HR imaging MS) opened doors to spatial profiling of hundreds of metabolites directly from tissue sections. However, clinical use of HR imaging MS is hampered by a lack of clinically-oriented bioinformatics tools for molecular interpretation of the complex and information-rich data produced. Our goal is to address this bottleneck. We will develop algorithms for high-throughput putative annotation of hundreds of metabolites, knowledge-based downstream analysis, and validation of biologically-relevant leads. We will create the METASPACE engine, an open online platform providing these tools integrated into validated workflows for clinical use. This engine will be evaluated in clinical case studies on metabolic phenotyping of tumor response to chemotherapy and polymicrobial infections in cystic fibrosis. This demonstration will raise awareness and build trust among potential end-users. METASPACE will create a research ecosystem for exploitation of spatial metabolomic data that benefits both academics and industry. An open-source approach will stimulate developments in this field and provide a sustainable platform capable of incorporating future bioinformatics. Our user-centred tools, linked to existing molecular databases, will enable researchers without mass spectrometry or bioinformatics experience to turn big and complex HR imaging MS data into molecular knowledge. A considerable outreach effort, alongside constant interaction with the clinical metabolomics community, will maximize impact and dissemination. By engaging and educating envisaged end-users, METASPACE will facilitate future clinical discoveries in studies that require untargeted metabolic profiling and imaging. Our project will drive innovation and create a novel bioinformatics research field centred in Europe.

Keywords: metabolomics,clinical metabolomics,high resolution mass spectrometry,imaging mass spectrometry,open online engine,tumor response to chemotherapy in esophageal cancer,cystic fibrosis
Innovative Glycan-based analysis for Cancer diagnostics (GlyCan)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Slovakia
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2018)
Start date: 2019-02-01
End date: 2019-08-31
Duration (months): 7.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Worldwide, there are 1.6M new prostate cancer (PCa) cases with 366k deaths annually. Novel PCa biomarkers are needed since the best current PCa biomarker (prostate specific antigen (PSA)) lacks PCa diagnostic accuracy often resulting in mistreatment of PCa patients. The false-positive rate of PSA in blood serum is ~75%. PSA test is applied together with digital rectal examination (DRE) for preliminary screening. If the combined results are suspicious, the patients undergo a biopsy to confirm PCa. Yet, there are 74% of needless biopsies representing a significant pain for PCa patients and societal/economic burden. Based on a great commercial outcome from the ERC grant (311532) granted to Dr. Jan Tkac (co-founder/CSO of Glycanostics), the company has developed an innovative, non-invasive, early PCa diagnostics using blood serum. Instead of quantifying PSA, the innovative PCa diagnostic assay detect glycan changes on PSA protein (it discriminates between “healthy” PSA and “sick” PSA and accurately quantify the clinically relevant “sick” PSA). The technology is covered by two EPO patent applications owned by the company. The PCa diagnostic test with 95% accuracy will be applied as a 2nd opinion test in case of suspicious results from PSA & DRE examinations prior sending to a biopsy. PCa DX kit will be launched for clinics/hospital & cancer centres (B2B) and Prostate check home test for user-friendly application at homes (B2C). Our PCa diagnostic technology is unique compared to our competitors focusing on analysis of other complex biomolecules such as a level of proteins, mRNA and circulating DNA. Moreover, we have competitive advantage over competitors in terms of cost per sample, assay accuracy, simplicity of the assay enabling the home testing and high-throughput. Glycanostics consists of 7 core team members, 4 business and 4 scientific advisors making a great and highly experienced team that will bring these innovative PCa early diagnostic products to the market.

Keywords: prostate cancer,personalised diagnostics,glycan analysis,lectins,clinical kit,home test
Generative European Commons Living Lab (gE.CO Living Lab)

Framework: Horizon 2020 — Societal Challenges
Programme: Europe in a changing world - inclusive, innovative and reflective societies
Theme: Innovative societies
Action type: Coordination and support actions
Countries involved: Italy,Spain,Spain,Austria,Italy,Belgium,Greece,United Kingdom
Call: Cities as a platform for citizen-driven innovation (H2020-SC6-TRANSFORMATIONS-2018, 2018)
Start date: 2019-02-01
End date: 2022-01-31
Duration (months): 36.0
Total project cost (EUR): 995810.0
EU funding (EUR): 995809.0
Participants: 8
Project status: CLOSED

gE.CO Living Lab aims at creating a platform for bringing together and supporting formal groups or informal communities of citizens who manage fab-lab, hubs, incubators, co-creation spaces, social centres created in regenerated urban voids. These innovative practices are considered generative commons, because they are based on sharing and collaboration between citizens and establish a new partnership between Public Institutions and local communities, setting forth new models of governance of the urban dimension based on solidarity, inclusion, participation, economic and environmental sustainability. However, these experiences design a scattered scenario of different legal and economic models which scalability is extremely difficult without appropriate tools. Also, their support through the traditional means of the public runs the risk of compromising their participatory character. To fill these gaps gE.CO built a consortium of experts: Universities and non-profit and for-profit organizations in order to: i) bring together generative commons using a digital platform for collaboration that will map citizens’ initiatives as well as those Public Institutions engaged in new forms of partnership with local communities. This way, generative commons and Public Administrations can finally be connected in a new network able to promote the exchange of good practices and legal solutions; ii) evaluate a group of pilot cases in order to understand which socio-economic, cultural and legal factors make self-organized experiences sustainable and Public Institutions helpful for their development; iii) use the results of the evaluation for scaling up sustainable generative commons and innovative local policies: best practices, recommendations as well as legal solutions will be developed for supporting the emergence of new generative commons through shared, public and open access contents.

Keywords: urban commons,citizens participation
Big Data 4 Better Hearts - Sofia ref.: 116074 (BigData Heart)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Public-private partnerships
Destination: Innovative Medicines Initiative 2
Action type: Research and Innovation actions
Partnership: IMI2 (Art-187)
Countries involved: Germany,Germany,Germany,Spain,Belgium,Sweden,Sweden,Switzerland,Switzerland,France,France,Netherlands,United States,United Kingdom,United Kingdom,United Kingdom
Call: INCREASE ACCESS AND USE OF HIGH QUALITY DATA TO IMPROVE CLINICAL OUTCOMES IN HEART FAILURE (HF), ATRIAL FIBRILLATION (AF), AND ACUTE CORONARY SYNDROME (ACS) PATIENTS (H2020-JTI-IMI2-2015-07-two-stage, 2015)
Start date: 2017-03-01
End date: 2023-02-28
Duration (months): 72.0
Total project cost (EUR): 19449971.66
EU funding (EUR): 9664970.0
Participants: 22
Project status: SIGNED

Despite remarkable progress in the management of cardiovascular disease (CVD), major unmet needs remain with regard to mortality, hospitalisations, quality of life (QoL), healthcare expenditures and productivity. Acute coronary syndrome (ACS), atrial fibrillation (AF) and heart failure (HF) are major and growing components of the global CVD burden. Optimal management of these conditions is complicated by their complex aetiology and heterogeneous prognoses. Poor definition at the molecular level and co/multi-morbidities form major challenges for the development and delivery of targeted treatments. This renders response to therapy unpredictable, with large inter-individual variation and, importantly, small or undetectable treatment effects in large trials of unselected patients. Today’s treatment guidelines still reflect the scientific constraints of an earlier era where clinical markers to guide therapy are limited to conventional risk factors and end-organ damage, and where the main endpoint in clinical trials is patient death. Hence, drug development pipelines from early target validation through to late post-marketing work have proven to be slow, expensive and high-risk: the chance of eventual approval for a CVD drug candidate in Phase I trials is 7%, the lowest of any disease category (shared with oncology) 2. Moreover, tolerability of medication and adherence to treatment show wide variations. There is thus a need for better definition of these diseases, their markers and endpoints (including better segmentation of current heterogeneous patient groups acknowledging underlying mechanisms and comorbidities) and of their outcomes/prognoses (including functional capacity and quality of life [QoL]). BigData@Heart’s ultimate goal is to develop a Big Data--driven translational research platform of unparalleled scale and phenotypic resolution in order to deliver clinically relevant disease phenotypes, scalable insights from real-world evidence and insights driving

Keywords: heart failure,atrial fibrillation,and acute coronary syndrome,cardiovascular disease
Assessing and improving the innovation management capacity of Walloon SMEs through specialized EEN services (KAMWAL)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: Coordination and support actions
Countries involved: Belgium,Belgium
Call: INNOSUP (H2020-Adhoc-2014-20, 2014)
Start date: 2014-09-01
End date: 2014-12-31
Duration (months): 4.0
Total project cost (EUR): 33430.0
EU funding (EUR): 26744.0
Participants: 2
Project status: CLOSED

The KAMWAL project aims to set up and to validate through some real-life cases two new kinds of advanced services for SMEs in the Walloon region of Belgium with the support and in the framework of the Enterprise Europe Network Wallonia consortium. These services are the KAM service, in the framework of the H2020 SME Instrument, in order to provide Walloon beneficiaries with dedicated and specialized coaching and the IMC service aiming to improve the Innovation Management Capacities in SMEs with high growth and international potential. The project is expected to cover the end of 2014 starting from dedicated trainings related to the IMP³ROVE tool which will be used by the EEN staff in charge. This EEN staff in charge will be composed of 2 experienced innovation consultants already member of the EEN Wallonia team. In the framework of the action, it is shown that the duration and the available means allow to work on a set of maximum 10 Walloon cases either with the KAM service or with the IMC service.

Keywords: entreprise europe network,wallonia,innovation,support
Smart in-line metrology and control for boosting the yield and quality of high-volume manufacturing of Organic Electronics (SmartLine)

Framework: Horizon 2020 — Industrial Leadership
Programme: Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology
Theme: Technologies for Factories of the Future
Action type: Innovation actions
Countries involved: Germany,Italy,Germany,Germany,Greece,Netherlands
Call: In-line measurement and control for micro-/nano-enabled high-volume manufacturing for enhanced reliability (H2020-FOF-2017, 2017)
Start date: 2017-09-01
End date: 2020-11-30
Duration (months): 39.0
Total project cost (EUR): 5424875.0
EU funding (EUR): 4262637.5
Participants: 8
Project status: CLOSED

SmartLine is an ambitious Project submitted to the H2020 Call FOF-08-2017 that will create intelligent and zero-defect manufacturing processes by developing robust and non-destructive in-line metrology tools (optical, electrical, structural) and process control platform to achieve the reliable and closed-loop manufacturing of Organic Electronic devices (OPVs and OLEDs for lighting) by unique R2R printing and OVPD pilot lines. The main objectives of the SmartLine proposal are the following: 1. Develop robust, non-destructive, and in-line optical (Spectroscopic Ellipsometry, Raman, Wavelength Scanning Interferometry, Reflectometry), and electrical metrology (Eddy Current measurement) tools and methodologies 2. Integrate in-line metrology tools in strategic parts of unique R2R printing and OVPD Pilot to Production Lines 3. Develop a Unique Platform for feedback from the in-line metrology tools to control the processes through non-destructive and traceable in-line measurements and algorithms, combined with contribution to standardization & reference materials 4. Optimize the R2R printing and OVPD manufacturing processes reliability in pilot lines, fabrication of homogeneous OPV and OLEDs and demonstration of their reliability and homogeneity to industrial applications (e.g. automotive). The above can be only addressed by a European approach and a transnational cooperation between excellent entities in characterization/modelling and industrial entities with unique pilot lines. This project will bring together academic, SME and industrial partners with world-class excellence and established track-record in metrology tools and manufacturing. This project will have a huge impact and will transform the manufacturing processes for Organic Electronics Industry and for other Industries as Thin Films (e.g. functional films, antimicrobial and decoration coatings, barriers), Electronics, Wearables, Energy, Automotive, Transport, Space, Health, etc, to the Factory of the Future.

Keywords: organic electronics,in line metrology tools,roll to roll printing,organic vapour phase deposition,pilot lines,organic photovoltaics,automotive